Close

UPDATE: Wells Fargo Reinstates Merck (MRK) at Overweight

December 8, 2021 4:19 PM EST
Get Alerts MRK Hot Sheet
Price: $131.95 +0.15%

Rating Summary:
    24 Buy, 4 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
(Updated - December 9, 2021 5:54 AM EST)

Wells Fargo analyst Mohit Bansal reinstates coverage on Merck (NYSE: MRK) with a Overweight rating and a price target of $90.00.

The analyst comments "Keytruda growth underappreciated as we see $2B upside potential to consensus by 2025. Street is also ignoring MRK's lifecycle management approach for Keytruda LOE. Readouts in 2023-26 should expand multiple. Business development underappreciated."

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $72.28 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Wells Fargo